21 August 2021: Clinical Research
Sevoflurane-Remifentanil Versus Propofol-Remifentanil Anesthesia During Noncardiac Surgery for Patients with Coronary Artery Disease – A Prospective Study Between 2016 and 2017 at a Single Center
Zhongliang Dai 1ACDE , Miao Lin 1BDE , Yali Li 1BE , Wenli Gao 1BDE , Ping Wang 1BDE , Juan Lin 1CE , Zhenzhen Wan 2AE* , Yuanxu Jiang 1CE*DOI: 10.12659/MSM.929835
Med Sci Monit 2021; 27:e929835
Table 1 Patient characteristics.
| Variables | Sevoflurane (n=81) | Propofol (n=83) | P |
|---|---|---|---|
| Age (years) | 72±7 | 73±8 | 0.651 |
| Male, n (%) | 76 (93.8) | 74 (89.2) | 0.452 |
| BMI (kg/m) | 26.2±3.6 | 26.1±3.4 | 0.735 |
| NYHA classification, n (%) | |||
| I | 25 (30.9) | 27 (32.5) | 0.832 |
| II | 38 (46.9) | 36 (43.4) | 0.712 |
| III | 13 (16.0) | 12 (14.5) | 0.545 |
| IV | 5 (6.2) | 8 (9.6) | 0.452 |
| ASA classification, n (%) | |||
| II | 10 (12.3) | 13 (15.7) | 0.231 |
| III | 63 (77.8) | 64 (77.1) | 0.893 |
| IV | 8 (9.9) | 6 (7.2) | 0.314 |
| History of CAD, n (%) | 65 (80.2) | 68 (81.9) | 0.492 |
| History of stroke, n (%) | 13 (16.0) | 12 (14.5) | 0.634 |
| History of diabetes mellitus, n (%) | 25 (30.9) | 24 (28.9) | 0.365 |
| β-blocker, n (%) | 71 (87.7) | 69 (83.1) | 0.478 |
| ACE/AT block, n (%) | 64 (79.0) | 65 (78.3) | 0.783 |
| Statins, n (%) | 63 (77.8) | 61 (73.5) | 0.325 |
| Insulin (with or without oral antidiabetic), n (%) | 8 (9.9) | 9 (10.8) | 0.297 |
| Oral antidiabetic drugs only, n (%) | 25 (30.9) | 23 (27.7) | 0.413 |
| Smokers, n (%) | 28 (34.6) | 26 (31.3) | 0.578 |
| Patients with hypertension, n (%) | 35 (43.2) | 36 (43.4) | 0.641 |
| Dyslipididemics, n (%) | 22 (27.2) | 24 (28.9) | 0.459 |
| BMI – body mass index; NYHA – New York Heart Association; ASA – American Society of Anesthesiologists; CAD – coronary artery disease; ACE – angiotensin-converting enzyme; AT – angiotensin. | |||